Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00451412 |
This study is designed to provide efficacy and safety data for certoparin in the prophylaxis of venous thromboembolism in immobilized, acutely ill medical patients.
Condition | Intervention | Phase |
---|---|---|
Thromboembolism |
Drug: Certoparin Drug: unfractionated heparin |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Multi-Center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients |
Estimated Enrollment: | 3200 |
Study Start Date: | January 2007 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Certoparin
3000 U anti XA of certoparin in 0.3 ml solution, once daily
|
2: Active Comparator |
Drug: unfractionated heparin
solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily
|
Ages Eligible for Study: | 70 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Contact: Novartis | +41 61 324 1111 |
Germany | |
Novartis investigative sites | Recruiting |
Nürnberg, Germany | |
Contact: Novartis +41 61 324 1111 | |
Principal Investigator: Novartis |
Study Director: | Novartis | Novartis |
Responsible Party: | Novartis ( External Affairs ) |
Study ID Numbers: | CMEX839BDE03 |
Study First Received: | March 21, 2007 |
Last Updated: | November 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00451412 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; Romania: National Medicines Agency |
Venous thromboembolism Medical patients Heparin Low molecular weight heparin |
Deep vein thrombosis Certoparin Embolism and Thrombosis |
Heparin, Low-Molecular-Weight Vascular Diseases Venous Thromboembolism Thrombosis Thromboembolism Calcium heparin Body Weight |
Calcium, Dietary Embolism and Thrombosis Embolism Venous Thrombosis Heparin Certoparin |
Fibrin Modulating Agents Anticoagulants Molecular Mechanisms of Pharmacological Action Therapeutic Uses Hematologic Agents |
Fibrinolytic Agents Cardiovascular Diseases Cardiovascular Agents Pharmacologic Actions |